Published July 23, 2023 | Version v1
Poster Open

Microenvironment of metastatic site reveals key predictors of PD-1 blockade response in renal cell carcinoma

Creators

  • 1. CEA
  • 2. Lund University
  • 3. University of St Andrews
  • 4. Centre hospitalier universitaire Grenoble Alpes
  • 5. Univ Rennes
  • 6. Memorial Sloan Kettering Cancer Center
  • 7. University of Gdansk
  • 8. Universidade de Lisboa
  • 9. University of Rome Tor Vergata
  • 10. Edinburgh Cancer Centre
  • 11. CNRS
  • 12. INSERM

Description

Immune checkpoint blockade (ICB) therapies are now an important tool in the arsenal for the treatment of advanced cancer extending progression-free survival and overall survival. However, only a subset of cancer patients responds to ICB therapies causing an urgent need for novel approaches to better select patients who may benefit from immunotherapy. Here, we used metastatic ccRCC samples obtained before ICB treatment and performed cell deconvolution analysis to investigate novel biomarkers of ICB treatment response.

Files

Jeanneret_ECCB-ISMB2023.pdf

Files (259.7 kB)

Name Size Download all
md5:4a427cfffbb43269effeb81d41cb6438
259.7 kB Preview Download

Additional details

Funding

CANVAS – Enhancing Cancer Vaccine Science for New Therapy Pathways 101079510
European Commission
KATY – Knowledge At the Tip of Your fingers: Clinical Knowledge for Humanity 101017453
European Commission